AA
BTAI icon

ALPS Advisors’s BioXcel Therapeutics BTAI Stock Holding History

ALPS Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,154
Closed -$344K – 1007
2023
Q1 		$344K Sell
1,154
-33
-3% -$14.1K ﹤0.01% 696
2022
Q4 		$408K Buy
1,187
+234
+25% +$56.6K ﹤0.01% 666
2022
Q3 		$180K Sell
953
-84
-8% -$19.5K ﹤0.01% 1009
2022
Q2 		$219K Sell
1,037
-760
-42% -$160K ﹤0.01% 978
2022
Q1 		$601K Sell
1,797
-226
-11% -$65.5K 0.01% 406
2021
Q4 		$658K Sell
2,023
-119
-6% -$51.1K 0.01% 453
2021
Q3 		$1.04M Buy
2,142
+115
+6% +$50.6K 0.01% 384
2021
Q2 		$943K Sell
2,027
-728
-26% -$397K 0.01% 405
2021
Q1 		$1.9M Buy
2,755
+20
+0.7% +$16.1K 0.02% 317
2020
Q4 		$2.02M Buy
2,735
+953
+53% +$742K 0.02% 275
2020
Q3 		$1.24M Buy
1,782
+59
+3% +$44.3K 0.02% 309
2020
Q2 		$1.46M Buy
+1,723
New +$1.12M 0.02% 264

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ALPS Advisors's BTAI Position: Q2 2023 in Review

ALPS Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 1,154 shares — an estimated $344K sold.

ALPS Advisors first reported a position in BTAI in Q2 2020 and held it in 12 quarters. The position peaked at $2.02M in Q4 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • ALPS Advisors reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 1,154 BioXcel Therapeutics shares in Q2 2023, an estimated $344K.
  • ALPS Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 12 quarters.
  • ALPS Advisors's BioXcel Therapeutics position peaked at $2.02M in Q4 2020.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.